91
Table 6 Oral and nasal administration of deep eutectic solvent formulations
Active agent
Deep eutectic solvent
composition
Results in vivo
References
Oral administration
Insulin
C:GE 1:2
Lowering of blood glucose in normal
rats
Banerjee et al.
(2018a)
None
C:GE 1:2
Reduced fat absorption; lower body
weight gain on high-fat diet
Nurunnabi et al.
(2019)
Rutin
P:GLA 2:1
Increased blood concentration;
improved pharmacokinetics
Faggian et al.
(2016)
Berberine
P:MA:LA:W
1:0.2:0.3:0.5
Increased blood concentration;
improved pharmacokinetics
Sut et al. (2017)
Salvianolic
acid B
CC:GL 1:2
Increased blood concentration;
improved pharmacokinetics
Chen et al.
(2017)
Curcumin
CC:GL 1:1
Increased solubility in gastric and
intestinal media
Jeliński et al.
(2019b)
Nasal administration
Insulin
CC:MA 2:1
Lowering of blood glucose in normal
rats
Li et al. (2019)
For abbreviations, see Table 1
Fig. 2.8 Plasma pharmacokinetics (mean ± SD) of berberine in Balb/c mice following oral administration of 50 mg/kg in NADES solution (A = proline:malic acid (1:2), B = proline:urea (2:1),
C = lactic acid:proline:malic acid:water (1:0.2:0.3:0.5)) or in suspension in water. (Sut et al. 2017)
2 Deep Eutectic Solvents for Innovative Pharmaceutical Formulations